Table 6.
Rank | Site | Property | Score | Prevalence | Status | |
---|---|---|---|---|---|---|
1 | P215 | E oct-wat. | 101.72 | 0.54 | Known for NRTIs (abacavir, didanosine, stavudine, tenofovir, zidovudine) | * |
3 | P210 | isoel. point | 82.64 | 0.26 | Known for NRTIs (abacavir, stavudine, tenofovir, zidovudine) | * |
11 | P67 | vdW vol. | 59.61 | 0.11 | Known for NRTIs (abacavir, stavudine, tenofovir, zidovudine) | * |
14 | P41 | isoel. point | 50.64 | 0.4 | Known for NRTIs (abacavir, didanosine, stavudine, tenofovir, zidovudine) | * |
27 | P151 | vdW vol. | 26.31 | A0.04 | Known for NRTIs (abacavir, didanosine, lamivudine, stavudine, zidovudine) | * |
29 | P75 | polarity | 22.94 | 0.09 | Known for NRTIs (stavudine) | * |
30 | P208 | isoel. point | 22.44 | 0.1 | Unknown | +++ |
31 | P118 | freq. helix | 22.24 | 0.17 | Known but considered unimportant | * |
33 | P44 | E oct-wat. | 21.59 | 0.1 | Known for NRTIs (tenofovir) | + |
35 | P69 | E oct-wat. | 21.02 | 0.15 | Known for NRTIs (abacavir, didanosine, lamivudine, stavudine, tenofovir, zidovudine) | * |
47 | P219 | freq. turn | 18.15 | 0.27 | Known for NRTIs (didanosine, stavudine, zidovudine) | * |
48 | P70 | vdW vol. | 17.83 | 0.28 | Known for NRTIs (didanosine, stavudine, tenofovir, zidovudine) | * |
52 | P116 | polarity | 16.93 | 0.03 | Unknown | +++ |
60 | P43 | freq. helix | 15.78 | 0.14 | Unknown | +++ |
94 | P218 | freq. helix | 8.31 | 0.08 | Unknown | +++ |
96 | P228 | isoel. point | 7.83 | 0.14 | Unknown | +++ |
100 | P203 | freq. turn | 7.45 | 0.12 | Unknown | +++ |
101 | P122 | vdW vol. | 7.17 | 0.48 | Unknown | +++ |
103 | P184 | E sol. wat. | 6.63 | 0.56 | Known for NRTIs (abacavir, didanosine, lamivudine) | + |
110 | P211 | polarity | 5.9 | 0.54 | Unknown | +++ |
111 | P62 | E sol. wat. | 5.85 | 0.05 | Part of the multi-nRTi resistance complex. Affects all NRTIs except Tenofovir | * |
Symbols represent the status of a site:
Sites known to contribute to resistance to Stavudine;
Sites where mutations are associated with resistance to some NRTI drugs but not to Stavudine;
Sites where mutations contribute to resistance to NNRTI drugs;